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Abstract
Osteoclasts are cells of hematopoietic origin with a unique property of dissolving bone; their
inhibition is a principle for treatment of diseases of bone loss. Protocols for generation of human
osteoclasts in vitro have been described, but they often result in cells of low activity, raising
questions on cell phenotype and suitability of such assays for screening of bone resorption
inhibitors. Here we describe an optimized protocol for the production of stable amounts of highly
active human osteoclasts. Mononuclear cells were isolated from human peripheral blood by density
centrifugation, seeded at 600,000 cells per 96-well and cultured for 17 days in α-MEM medium,
supplemented with 10% of selected fetal calf serum, 1 µM dexamethasone and a mix of
macrophage-colony stimulating factor (M-CSF, 25 ng/ml), receptor activator of NFκB ligand
(RANKL, 50 ng/ml), and transforming growth factor-β1 (TGF-β1, 5 ng/ml). Thus, in addition to
widely recognized osteoclast-generating factors M-CSF and RANKL, other medium supplements
and lengthy culture times were necessary. This assay reliably detected inhibition of osteoclast
formation (multinucleated cells positive for tartrate-resistant acid phosphatase) and activity
(resorbed area and collagen fragments released from bone slices) in dose response curves with
several classes of bone resorption inhibitors. Therefore, this assay can be applied for monitoring
bone-resorbing activity of novel drugs and as an clinical test for determining the capacity of blood
cells to generate bone-resorbing osteoclasts. Isolation of large quantities of active human osteoclast
mRNA and protein is also made possible by this assay.
Background
Osteoclasts are highly differentiated cells of hematopoi-
etic origin that resorb bone in the organism, and are the
only cell type able to resorb bone from the bone slices in
vitro. Other main characteristics of osteoclasts are: tar-
trate-resistant acid phosphatase (TRAP) staining (shared
with macrophages), multinuclearity, formation of actin
ring structure and a polar cell body during resorption, and
contraction in response to calcitonin. Osteoclasts express
a number of molecular markers, such as calcitonin
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receptor, RANK (receptor of RANKL, receptor activator of
NFκB ligand), c-fms (receptor of M-CSF, macrophage-col-
ony stimulating factor), cathepsin K, c-src, fosL1 and the
vitronectin receptor (integrin αvβ3). Osteoporosis is a dis-
ease of low bone mass and increased fracture rate,
commonly occurring in aged population and increasing
in women after menopause. Drugs for osteoporosis treat-
ment comprise several classes of compounds with anti-
resorptive properties and a search for better drugs is ongo-
ing. Therefore, an in vitro cell culture system for assaying
the number and activity of osteoclasts would have an
important role in discovering new osteoporosis drugs.
Currently, no such system with isolated primary human
osteoclasts has been described.
Classically, osteoclasts have been generated in co-cultures
of osteoblasts or stromal cells and hematopoietic cells
from spleen or bone marrow. Since the breakthrough dis-
covery of RANKL (also named OPGL, ODF) in 1998,
which was identified as osteoblast-produced ligand pro-
moting osteoclast differentiation; it has become possible
to generate bone-resorbing osteoclasts without the need
for co-culture [1]. RANKL (together with M-CSF) could be
added directly to the cultures of osteoclast precursors to
generate mature, active osteoclasts. This provided impor-
tant advantages over previous co-culture systems, as it
enabled the work with the cells from one lineage and, at
the end of the culture, with pure osteoclasts. Early reports
on RANKL-dependent culture systems described the con-
ditions for generation of human osteoclasts from the
peripheral blood mononuclear cells (PBMNC) [2,3].
These protocols were similar in the use of RANKL, M-CSF
and dexamethasone or hydrocortisone, but differed in the
use of PBMNC fraction (adherent plus non-adherent or
only adherent cells), the length of the assay (7–12 days vs.
14–21 days), concentration of M-CSF, seeding cell density
and the source of RANKL cytokine. TGF-β1 was not
included in the culture medium in both of these methods.
While these reports were an important scientific advance
by showing that it is possible to generate human osteo-
clasts from PBMNC, the described conditions were not
robust enough to ensure production of highly active cells
in a relatively stable fashion. Similar results were obtained
when a method for osteoclast formation from human
bone marrow cells [4] was adapted to PBMNC and when
M-CSF and RANKL were used instead of the co-culture
with osteoblasts. The application of these protocols in our
laboratory produced TRAP-positive cells, but their forma-
tion was not RANKL-dependent and the bone resorption
activity of the cells was poor (only few percent of bone
slice area resorbed). With the aim to set up a reproducible
system that is amenable to screening and pharmacological
characterization of drugs with bone resorbing properties,
we have optimized the conditions for human osteoclast
generation. Three different, simple read-outs were used to
measure osteoclast numbers and activity. This system has
been used over extended periods of time, enabling phar-
macological characterization of several classes of known
bone resoprtion inhibitors, for the first time with human
primary osteoclasts. There are several possible applica-
tions of this assay: a) as a low to medium throughput
screening system for anti-resorptive agents, b) as a source
of human osteoclast RNA and protein, and c) as a clinical
assay, whose a diagnostic value could be estimated by test-
ing various patient populations.
Methods
Isolation of human peripheral blood mononuclear cells 
(PBMNC)
Either whole blood (about 50 ml) or the "buffy coat" cell
preparation from about 450 ml of whole blood from male
volunteers (up to 40 years of age) was provided by the
Transfusion Center, Basel. These cells were once more
purified over the Ficoll-Paque: 15 ml of whole blood or
"buffy coat" was mixed with 15 ml of warm (37°C) phos-
phate-buffered saline (PBS, without Ca2+ and Mg2+), lay-
ered over 15 ml of Ficoll-Paque (Amersham Pharmacia
Biotech, Uppsala, Sweden) and centrifuged (1500 g, 30
min, room temperature, without the brake). The cell layer
on top of the Ficoll-Paque was collected, resuspended in
10 ml of warm PBS (without Ca2+ and Mg2+), diluted with
40 ml PBS and centrifuged (1500 g, 15 min, room temper-
ature, with the use of brake). Subsequently, cells were
counted in a hematocytometer, and used immediately, or
aliquoted, frozen and stored in liquid nitrogen.
Culture conditions for human osteoclastogenesis assays
Whole population of PBMNC (fresh or thawed) was
plated in 96-well plates at 6 × 105 cells per well in 0.2 ml
of medium (α-MEM, Gibco, pH 7.4, containing 10% FCS
from Amimed, batch #S03485). Medium was also supple-
mented with the following cytokines, growth factors and
hormones: 25 ng/ml human M-CSF (R&D Systems,
Abingdon, UK), 50 ng/ml human RANKL (Insight Bio-
technology, Wembley, UK), 5 ng/ml human TGF-β1
(R&D Systems, Abingdon, UK), and 1 µM dexamethasone
(Sigma, Buchs, Switzerland). The cells were re-fed twice
weekly by demi-depletion (half of the medium with-
drawn and replaced with the fresh medium). The culture
duration was 17 days for both TRAP staining and pit
assays.
For pit assays the cells were plated from the beginning of
the culture on top of sterile bovine cortical bone or ivory
dentin slices placed in 96-well plates. The culture condi-
tions were as described above.
Remarks
A) Purification of osteoclast precursors from PBMNC with
CD14 and CD34 antibodies was reported [5,6]. This is notJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/6
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necessary in our method, making the protocol simpler
and cheaper. B) Serum was batch-selected. C) RANKL
from Insight Biotechnology was more active than RANKL
from PeproTech EC Ltd. (London, UK). D) Osteoclast for-
mation phase lasted until day 8–10 (cell morphology,
expression of molecular markers and the start of bone
resorption). The rest of the culture period is necessary for
osteoclast maturation and full activation.
TRAP and pit assays
TRAP staining of adherent cultures was done with a kit
from Sigma (Buchs, Switzerland) exactly according to
manufacturer's instruction (Procedure No. 386). The
stained cells developed red color of different intensity. For
measurement of resorbed area in the pit assay, the bovine
cortical bone or dentin slices were washed with PBS, incu-
bated in 5% sodium hypochlorite for 10 min, washed
twice with water, and stained with 0.1% toluidine blue.
The pits developed blue to purple color.
Quantification of TRAP-positive multinucleated cell 
number and area of resorbed bone
The number of TRAP-positive multinucleated cells and
the area of resorbed bone in the pit assay were determined
using the 1 × 1-mm grid placed in the ocular of the micro-
scope. For TRAP assay, Zeiss Axiovert 100 microscope
(Zeiss, Oberkochen, Germany) was used; and for pit assay
Leitz Laborlux S microscope (Leica AG, Glattbrugg, Swit-
zerland) was used.
In the TRAP assay, the number of TRAP-positive multinu-
cleated cells (>2 nuclei per cell) was measured at predeter-
mined sites of the area of 1 × 1 mm. Five sites were
measured in a well of a 96-well plate, and a mean value
was calculated. Four wells were measured in total per one
condition and these results were expressed as mean ±
SEM. Typical values for the number of TRAP-positive
multinucleated cells in controls were about 400–600 cells
per well (96-well plate).
In the bone resorption pit assay, four bovine cortical slices
were assessed per one condition, each in one well on 96-
well plate. Quantification was done on the whole bone
slice area (3 × 3 mm on 96-well plates). The results were
expressed as mean ± SEM. Typical values for resorbed
areas in controls were between 25 and 50%. In some
experiments, ivory dentin slices were used. All slices were
prepared by cutting blocks of bone or dentin at 0.3 mm
thickness with a low speed saw using water cooling (Iso-
met, Buehler, Lake Bluff, Illinois, USA).
Remarks
A) Cell number was optimized in titration experiments
using 1, 3, 6, and 10 × 105 PBMNC per well of a 96-well
plate. B) TRAP-stained area per well (represents both
mononuclear and multinuclear cells) was also measured,
but it did not correlate with the bone resorption activity of
osteoclasts. Thus, we do not recommend total TRAP meas-
urements, either as areas or as enzyme activity in cell
lysates, as read-outs for osteoclast formation. C) Pits pro-
duced on dentin slices were easier to measure than pits on
cortical bone slices (a more regular shape, absence of
stained structures on dentin, and low background stain-
ing). Osteoclasts released higher amounts of collagen
fragments in dentin. However, bovine cortical slices were
routinely used for screening procedures because of easier
accessibility and lower costs. D) For drug screening pur-
poses, the osteoclast resorption activity should be >10%
of resorbed area. E) Higher resorption was obtained with
culture duration of 17 days, than of 10 and 14 days.
Quantification of collagen fragments by CrossLaps ELISA
For CrossLaps assay with human osteoclasts, the condi-
tioned culture medium was collected three days after
medium change at the end of the culture (day 17). Colla-
gen fragments (CTx) were quantified using the serum
CrossLaps™ one step ELISA kit (Osteometer, Herlev, Den-
mark). Aliquots of 50 µl were assayed directly or diluted
1:5 with the assay buffer, according to the instructions of
the manufacturer. Samples of culture medium from wells
containing bone slices without cells were also measured.
If such values exceeded 100 pM, they were subtracted
from values obtained for samples with cells. The occa-
sional minus values in the assay were adjusted to zero.
Typical values for control collagen fragment concentra-
tion after 17 days were 10–35 nM, depending on the oste-
oclast activity and the choice of slice material (bone or
dentin).
Microphotography
Microphotography was done with Leica Fluovert FS
microscope, Leica DC300 digital camera (Wetzlar, Ger-
many) and Leica IM 50 software (Leica Imaging Systems,
Cambridge, England).
Remarks
We recommend taking microphotographs of both cells
and pits, at least at the method set-up stage. They provide
valuable information on the quality of the assay.
Compounds
Zoledronic acid, raloxifene and AAR494 were synthesized
in the Novartis Chemistry laboratories. E-64 was pur-
chased from Sigma (Buchs, Switzerland). Zoledronic acid
was dissolved in sterile water, while the other three com-
pounds were dissolved in dimethyl sulfoxide (DMSO). All
compound stock solutions were 10 mM and were stored
as aliquots at -20°C. For dose response curves, compound
stock solutions were serially diluted in the culture
medium.Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/6
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IC50 value determination
The IC50 values were calculated from dose response curves
in each experiment using the curve fitting with the soft-
ware Origin 7 (OriginLab Corporation, Northampton,
USA).
RNA isolation and radioactive quantitative RT-PCR
Cells have been harvested in a guanidinium isothiocy-
anate containing buffer and total RNA was extracted,
treated with DNAse I and purified according to the manu-
facturer's instructions (RNeasy mini kit, QIAGEN, Swit-
zerland). The yields of RNA were 2–3 µg/well of a 6-well
plate or about 200 µg per one buffy coat (about 450 ml
blood). The yields of protein were 1 mg/10 cm plate or
about 10 mg per one buffy coat.
Reverse transcription (RT)
First strand complementary DNA was synthesized accord-
ing to standard protocols. Polymerase chain reaction
(PCR): One µl of diluted cDNA or RT(-) controls was
used. PCR was performed in a final volume of 25 µl, con-
taining 100 µM of each dNTP, 1 µCi of α[32P]-dATP, 1 µM
of each primer and 1.25 units of "hot start" thermostable
DNA polymerase and the corresponding reaction buffer
(FastStart Taq, ROCHE Molecular Diagnostics, Switzer-
land). The amplification protocol consisted of an initial
step of 5 min at 95°C, then desired number of cycles of
denaturation at 94°C for 1 min, annealing at 57°C (with
some exceptions) for 1 min, and extension at 72°C for 2
min. The final cycle included incubation at 72°C for 10
min.
Aliquots of PCR products, supplemented with a loading
buffer (final concentrations: 5% glycerol, 10 mM EDTA,
0.01% SDS, 0.025% xylene cyanol and bromophenol
blue dyes), were fractionated on 8% polyacrylamide gels.
The gels were vacuum-dried and exposed to phosphor-
storage screens (Molecular Dynamics, USA). Gel pictures
and quantification of signals have been obtained after
scanning with PhosphorImager SF and ImageQuant soft-
ware analysis (Molecular Dynamics, USA). Each primer
set was first pre-tested in cycle curve experiments to deter-
mine the linear range and the optimal cycle number.
Human primer sequences for osteoclast markers
18S rRNA: Forward: 5'-ACGGGGAATCAGGGTTCGA-3',
Reverse: 5'-CTCGAAAGAGTCCTGTATT-3'; product size
141 bp; annealing at 57°C, linear at 8–14 cycles;
TRAP: Forward: 5'-GATCCTGGGTGCAGACTTCA-3',
Reverse: 5'-GCGCTTGGAGATCTTAGAGT-3'; product size
210 bp; annealing at 57°C, 20 cycles;
Cathepsin K: Forward: 5'-ACCGGGGTATTGACTCTGAA-
3',
Reverse: 5'-GAGGTCAGGCTTGCATCAAT-3'; product size
190 bp; annealing at 57°C, 22 cycles;
RANK/TNFRSF11A: Forward: 5'-TGTGGCACTGGAT-
CAATGAG-3',
Reverse: 5'-GTCTTGCTGACCAATGAGAG-3'; product
size: 262, annealing at 57°C, 33 cycles;
Calcitonin Receptor: Forward: 5'-GACAACTGCTGGCT-
GAGTG-3',
Reverse: 5'-GAAGCAGTAGATGGTCGCAA-3', product
size 321 bp, annealing at 57°C, 33 cycles;
c-src: Forward: 5'-CCAGGCTGAGGAGTGGTATT-3',
Reverse: 5'-CAGCTTGCGGATCTTGTAGT-3', product size
193 bp, annealing at 57°C, 27 cycles;
Fosl1: Forward: 5'-CAGGCGGAGACTGACAAACT-3',
Reverse: 5'-TGCTGGTGCCACTGGTACT-3', product size:
172 bp, annealing at 57°C, 33 cycles
c-fms: Forward: 5'-GGCTCCTGGGCCTTCATACC-3',
Reverse: 5'-CAAAGGCTCCAGCTCCGAGG-3', product
size 301 bp, annealing at 66°C, 25 cycles;
Integrin beta3: Forward: 5'-TCGAGTTCCCAGTGAGT-
GAG-3',
Reverse: 5'-GACAGGTCCATCAAGTAGTAG-3'; product
size 202 bp, annealing at 60°C, 30 cycles.
Results
With an aim to develop a human osteoclast assay suitable
for drug screening, we have optimized the existing proto-
cols for osteoclast generation from blood cells. PBMNC
were used directly after centrifugation with Ficoll, without
any further enrichment. Initially, we tried to optimize
osteoclast generation using the existing protocols [2,3].
However, even dexamethasone alone, without M-CSF and
RANKL, could induce formation of TRAP-positive cells
(for example, TRAP-positive cell area was 1.2 ± 0.1% with
medium plus FCS, 27.4 ± 3.9% with medium, FCS and
dexamethasone, and 24.3 ± 1.4% with medium, FCS, dex-
amethasone, M-CSF and RANKL; values are means ±
SEM). The activity of generated cells was either completely
missing or was rather low, indicating that the number of
mature, active osteoclasts was low and that generated cellsJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/6
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Generation of highly active human osteoclasts from peripheral blood mononuclear cells: a requirement for TGF-β1 Figure 1
Generation of highly active human osteoclasts from peripheral blood mononuclear cells: a requirement for TGF-β1. Human 
osteoclasts were generated from peripheral blood mononuclear cells (PBMNC) as described under Materials and Methods. 
The medium contained either a mix of 10% FCS, dexamethasone (1 µM), M-CSF (25 ng/ml) and RANKL (50 ng/ml) (- TGF-β1) 
or this mix with 5 ng/ml TGF-β1 (+ TGF-β1). Number of TRAP-positive multinucleated cells and area of resorbed bovine bone 
or dentin was quantified microscopically. Upper panel: Quantification of TRAP-positive multinucleated cell number and pit 
area. The results are shown as means ± SEM; n is a number of independent experiments. Middle panel: Microphotographs of 
TRAP-stained cells on plastic and of toluidine blue-stained pits on dentin. Bottom panel: Molecular characterization of cells 
during osteoclast differentiation from PBMNC. Total RNA was extracted at the indicated times and expression of 8 osteoclast 
markers and 18S rRNA was measured by radioactive quantitative RT-PCR. RT-: reverse transcription omitted. OSM: osteo-
clast stimulating medium, containing the above mix of serum, dexamethasone, M-CSF, RANKL, and TGF-β1. No OSM cultures 
contained medium and FCS only. B: bone slices; D: dentin slices. Nd: not determined.
TGF-β1 Without With Fold
TRAP (MNC No.) 164±41 (7) 558±39 (31) 3.4x
PIT (D, % area) 5.3±2.2 (7) 43.0±6.0 (16) 8.1x
PIT (B, % area) nd 41.0±4.0 (31) nd
- TGF-β1 + TGF-β1
TRAP
PIT
CalcR
RANK
c-Fms
TRAP
CathK
c-Src
FosL1
Intβ3
18S
OSM: - - + - + - + - + RT(-)
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are most likely macrophage polykaryons. Subsequently,
we tested the addition of TGF-β1 to the cultures, although
controversial reports existed on its effects on human oste-
oclast formation [7,8]. In the presence of 10 % FCS, M-
CSF, RANKL and dexamethasone, TGF-β1 had a dramatic
stimulating effect on the bone-resorbing activity of gener-
ated human osteoclasts, enhancing their activity by 8-fold
(Fig. 1 upper and middle panels). The osteoclasts gener-
ated in the presence of TGF-β1 were also more multinucle-
ated. They expressed a full set of eight osteoclast markers
from day 8–17, confirming the cell phenotype at the
molecular level (Fig. 1, lower panel, OSM+ samples).
However, the cells without the medium supplements also
expressed all markers from day 13–17, were partly TRAP-
positive, but were not active in the pit assay (Fig. 1, lower
panel, OSM- samples, and data not shown). Thus, the pit
assay is necessary for the confirmation of mature osteo-
clast phenotype. In all subsequent experiments, we used
the above culture conditions to generate osteoclasts.
To run drug screening assays, it would be advantageous to
have a large, stable pool of PBMNC to work with. There-
fore, we examined the effect of cell freezing and pooling
on the osteoclast generation and activity (Fig. 2). Fifteen
frozen-thawed PBMNC batches from different donors
exhibited variable potential in forming TRAP-positive
multinuclear cells (Fig. 2, upper panel) and even larger
variation in their ability to resorb bone (Fig. 2, middle
panel). Importantly, these two parameters did not change
in parallel. Six batches of freshly isolated PBMNC were
analyzed and among them the variation was smaller.
Freezing-thawing did not have a big effect on osteoclast
formation or activity (Fig. 2, bottom panel). Thus, for
large analyses we collected PBMNC from several donors,
froze them, and tested them individually for osteoclast
formation and activity. Then, we pooled only those
PBMNC batches that showed good activity (>30% area of
bone slice resorbed). This enabled us to test different com-
pounds on the homogenously active cell population.
For some compounds, such as cathepsin K inhibitors,
resorbed area may not be a sensitive read-out, as the pit
depth and volume are affected more than the pit area [9].
Therefore, in addition to measuring TRAP-positive multi-
nucleated cell number and area of resorbed bone, we
established a third read-out, reflecting the pit volume and
a degree of collagen degradation in the bone slice. We
used human-specific CrossLaps ELISA assay for measuring
CTx collagen fragments. This assay was effective with both
ivory dentin and bovine bone (Fig. 3). The highest signal
was obtained in the conditioned medium collected at the
end of culture period (day 14–17). The bisphosphonate
zoledronic acid inhibited collagen fragment release in all
conditions examined (Fig. 3).
The effects of several known bone resorption inhibitors
were measured in the human osteoclast assay. We used
representative compounds for bisphosphonates
(zoledronic acid), selective estrogen receptor modulators
(SERM, raloxifene) and cathepsin K inhibitors (E-64 and
AAR494). These compounds have different mechanisms
of action and it was interesting to evaluate whether the
assay would detect these differences. The control osteo-
clast cultures at day 17 contained only TRAP-positive cells
and were almost confluent (Fig. 4, TRAP). Osteoclasts
were of various sizes: very large cells, smaller multinucle-
ated cells, and small mononucleated cells (Fig. 4, TRAP,
C). In the control cultures on bone slices, pits covered
most of the bone slice surface and formed characteristic
resorption tracks, resulting from osteoclast migration (Fig.
4, PIT, C). The bisphosphonate zoledronic acid (50 nM)
and selective estrogen receptor modulator (SERM)
raloxifene (100 nM) reduced osteoclast number, leaving
the culture largely depleted from mononuclear and
smaller multinuclear cells (Fig. 4, TRAP, Z.A., Ral.). At
these concentrations both compounds partially inhibited
pit formation (Fig. 4, PIT, Z.A., Ral.). Two cathepsin K
inhibitors were tested, a non-selective cysteine protease
inhibitor E-64 and a selective inhibitor AAR494. Both
compounds did not affect osteoclast formation, but
partially inhibited pit formation (Fig. 4, E-64, AAR).
AAR494 in particular induced changes in cell morphol-
ogy, evident as densely TRAP-stained regions within cells.
In addition, the remaining pits after treatment with this
compound did not have a track appearance, but were clus-
ter-like, containing small round pits.
The same bone resorption inhibitors were analyzed for
their efficacy and potency in dose-response curves for
three assay read-outs: osteoclast formation (multinucle-
ated cells), osteoclast activity as resorbed area and as
collagen fragments (Fig. 5). All three parameters changed
in parallel upon treatment with zoledronic acid and
raloxifene; however, raloxifene exerted only a partial
effect, while zoledronic acid was fully effective. By con-
trast, cathepsin K inhibitors produced dose response
curves that diverged. Multinucleated cell number curve
stayed unaffected at all concentrations. The resorbed area
dose response curve showed a decline, but maximal
effects were still partial. As expected, dose response curve
for collagen fragments was most sensitive towards cathep-
sin K inhibitors. The non-selective inhibitor E-64 was
more potent in suppressing collagen fragment release
than the selective cathepsin K inhibitor AAR494.
These data together indicated that this assay is suitable for
low to medium throughput screening of bone resorption
inhibitors. We confirmed this during more than two years
of experience with this assay.Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/6
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Individual variation in osteoclast generation and activity from different donors, and the effects of cell freezing-thawing Figure 2
Individual variation in osteoclast generation and activity from different donors, and the effects of cell freezing-thawing. Human 
osteoclasts were generated from peripheral blood mononuclear cells (PBMNC) as described under Materials and Methods. 
The results from 21 donors are presented as quantification of TRAP-positive multinucleated cell number (upper panel), and as 
resorbed area in the pit assay (middle panel). The results are summarized in the bottom panel. The results are shown as means 
± SEM; n is a number of independent experiments. PBMNC were used either after freezing-thawing or as freshly isolated cells. 
B: bone slices.
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Discussion
We have optimized culture conditions for generation of
human osteoclasts from human PBMNC to produce up to
2,200 cells/cm2 that were active by resorbing up to 80%
area of the bone slice. Main distinguishing features of our
protocol are: a) use of non-purified PBMNC, b) presence
of a combination of TGF-β1 and dexamethasone from the
start of the culture, in addition to well known osteoclas-
togenic factors M-CSF and RANKL, c) use of only commer-
cial and not self-made reagents, enabling reproducibility,
d) the length of cultures (>14 days), and e) pre-testing of
cells from various donors to avoid individual variation.
A number of cytokines has been described to stimulate
human osteoclast generation and /or activity, such as
prostaglandin E2, interleukin-1α, tumor necrosis factor-α
[10]. TGF-β, however, was reported to either inhibit or
stimulate human osteoclast formation [7,8]. Our data
show that TGF-β1, but not TGF-β3 (data not shown), in
presence of dexamethasone, M-CSF and RANKL, has a
major positive impact on osteoclast activity and a smaller
effect on the osteoclast formation. During the course of
our work others have also reported stimulatory effects of
TGF-β1, but in the absence of dexamethasone [11]. The
removal of non-adherent PBMNC was shown to increase
human osteoclast formation to the level induced by TGF-
β [11]. The removal of non-adherent cells would have
Establishment of a collagen fragment release read-out with dentin and bone slices Figure 3
Establishment of a collagen fragment release read-out with dentin and bone slices. Collagen fragments released from the pits 
on dentin or bone slices were measured in the cell culture medium with CrossLaps ELISA kit. The medium was collected after 
3 days of cell culture at the indicated times (for example, day 10 contains medium from days 7–10). The cultures were treated 
from the start with the vehicle PBS or with 50 nM zoledronic acid. The numbers over the bars for treated samples are % inhi-
bition relative to the corresponding control.Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/6
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The effects of several bone resorption inhibitors on human osteoclast and resorption pit morphology Figure 4
The effects of several bone resorption inhibitors on human osteoclast and resorption pit morphology. Human osteoclasts 
were generated as described under Materials and Methods, with or without the presence of bone resorption inhibitors: 
zoledronic acid (Z.A., 50 nM), selective estrogen receptor modulator (SERM) raloxifene (Ral., 100 nM), non-specific cathepsin 
K inhibitor E-64 (100 nM), and selective cathepsin K inhibitor AAR494 (AAR, 100 nM). Microphotographs show TRAP-stained 
cell morphology at culture day 17 (left panels) and pit morphology on dentin (control, zoledronic acid and raloxifene) or 
bovine bone (E-64 and AAR494). C, control. The activities (IC50 values) of E-64 and AAR494 on cathepsin K, S and L were (E-
64: 1.4; 4.1; 2.5 nM, and AAR494: 3.4; 3700; >10000 nM, respectively).Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/6
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been a cheaper and simpler protocol for production of
human osteoclasts than the addition of TGF-β1. However,
we did not detect any positive impact of the removal of
non-adherent cells (data not shown), suggesting that the
effect of TGF-β1 is not due to the presence of lymphocytes
in blood cell cultures, as proposed. Thus, we continued to
use TGF-β1. In agreement with a small positive effect on
osteoclast formation, TGF-β1 did not enhance osteoclast
markers (data not shown). The mechanism used by TGF-
β1 to stimulate osteoclast activity remains to be
determined.
The described assay is the first human primary osteoclast
assay that has been adapted for drug screening. Previous
osteoclast assays for measurement of compound activity
were either done with non-human cells (mouse, rat, rab-
bit) [12-14], or, if they used human cells, were done with
a human monocytic cell line in co-cultures with osteob-
lastic cells [15], or used human bone marrow-derived
Dose response curves for zoledronic acid, raloxifene, E-64 and AAR494 in the human osteoclast assay: measurements of oste- oclast formation, pit area and collagen fragment release Figure 5
Dose response curves for zoledronic acid, raloxifene, E-64 and AAR494 in the human osteoclast assay: measurements of oste-
oclast formation, pit area and collagen fragment release. Human osteoclasts were generated as described under Materials and 
Methods in the presence of increasing concentrations of compounds, as indicated. At the end of the 17 day-culture three quan-
titative read-outs were measured: the number of TRAP-positive multinucleated cells on the plastic, the resorbed area on bone 
slices, and the concentration of collagen fragments in the medium. The graphs were generated with Sigma Plot, and concentra-
tions inducing 50% inhibition (IC50 values) were calculated after curve fitting by the software Origin 7. The following IC50 values 
are means ± SEM from 3 independent dose response curves, in which each measurement was done in quadruplicates. The IC50 
values are shown in the order: cell number, resorbed area, and collagen fragments: zoledronic acid (102 ± 4; 173 ± 127, 182 ± 
150 nM), raloxifene (17 ± 3; 29 ± 13; 46 ± 13 nM), E-64 (>1000; 17 ± 2; 4 ± 3 nM), and AAR494 (>1000; 127 ± 105; 56 ± 27 
nM).Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/6
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osteoclasts [4], or human tumor osteoclastoma-derived
cells [9]. Although useful, these methods do not use active
primary human osteoclasts. Furthermore, obtaining
tissues required for osteoclast precursor isolation in these
methods is more difficult than obtaining human blood.
To test reproducibility and predictability of human osteo-
clast assay, the IC50 values were determined for three
known classes of bone resorption inhibitors, some of
which have already been tested in clinical studies:
bisphosphonates, SERM, and cathepsin K inhibitors. A Src
kinase inhibitor was also tested and was active, but it was
not characterized in detail (data not shown). Zoledronic
acid is the most potent bisphosphonate known [16]. In
primary human osteoclast assay, all three read-outs
decreased in parallel, indicating that main effect of
zoledronic acid was on osteoclast number, in agreement
with the notion that N-containing bisphosphonates
induce osteoclast apoptosis [17].
Estradiol and the SERM raloxifene are known inhibitors of
bone resorption in vivo, which were recently demon-
strated to exert direct effects on mouse osteoclasts [18].
Such effects have not been shown so far with human oste-
oclasts. Both compounds were active in human osteo-
clasts (estradiol data not shown), but, in contrast to
bisphosphonates, the maximal inhibition by raloxifene
and estrogen remained partial. Interestingly, this in vitro
result correlates well with a better efficacy of bisphospho-
nates as compared to estrogen and SERM in the retrospec-
tive analyses of clinical studies [19]. Although other
factors, such as pharmacokinetics and adverse effects,
influenced the outcome of clinical studies, our in vitro
data show that even at the level of osteoclasts, there is a
limited potential of SERM to inhibit bone resoprtion.
A non-specific and a specific cathepsin K inhibitor were
tested in the human osteoclast assay. Both compounds
did not affect osteoclast number, in agreement with the
notion that their target is a protease involved in bone
resorption, but not in osteoclast formation. Human oste-
oclast activity was dose-dependently inhibited, with
collagen release showing stronger inhibition, again in
agreement with the mechanism of action of these inhibi-
tors. E-64 was more potent, but not more effective than
AAR494, suggesting that other cathepsins play a minor
role in bone resorption. Our results with E-64 differ from
those generated in rat osteoclasts, where resorption area
was almost unaffected by the compound [14]. This appar-
ent discrepancy may represent a difference in species or in
experimental conditions, as our human assay is much
longer than the rat assay. We detected a peculiar, cluster-
like morphology of pits remaining after treatment with
AAR494, suggesting that the compound caused osteo-
clasts to interrupt the process of resorption. This phenom-
enon appears to be due to inhibition of osteoclast motility
and deserves further examination.
An additional application of the human osteoclast assay
could be in the clinic. Already limited analyses of about
20 samples from a rather homogenous population of
male blood donor volunteers younger than 40 years
showed a considerable variation in the ability of PBMNC
to form active osteoclasts. As small amounts of blood
(<10 ml) suffice for generation of osteoclasts, patients
could be screened for the ability of their circulating osteo-
clast precursors to generate osteoclasts. Osteoporotic,
normal and other patient categories could be examined
and a correlation between activity of osteoclast precursors
and disease occurrence and progression could be
evaluated.
Conclusions
We conclude that modified conditions for in vitro gener-
ation of human osteoclasts from peripheral blood result
in a stable generation of active osteoclasts. As documented
by testing several classes of bone-resorption inhibitors,
this assay can be used for screening novel drugs. As this
assay can be easily performed with a small volume of
human blood, it can also be used to monitor the capacity
of blood cells to generate bone-resorbing osteoclasts.
Competing interests
The authors are employed by the Novartis Institutes for
BioMedical Research.
Authors' contributions
N-H. L-N. performed all experimental studies, except
measurements of collagen fragments, and prepared the
Figures. RG supervised collagen fragment assays. DC
designed the primers for osteoclast markers and tested
most of them by radioactive quantitative RT-PCR. NZ
supervised N-H. L-N. in radioactive quantitative PCR. MS
conceived the study, supervised the experimental work
and wrote the manuscript. All authors read and approved
the final manuscript.
Acknowledgements
We thank Roger Vuille for his technical assistance with the CrossLaps 
ELISA, Martin Missbach and Rene Lattmann for the synthesis of AAR494 
and information on its selectivity, and Yves Seltenmeyer for the help in 
preparation of bone and dentin slices. Kind advice on bone marrow osteo-
clast generation and bone resorption assays by Usha Sarma, John Scopes, 
Helen Massey and Cheryl Lader (Flanagan laboratory, St. Mary's Hospital, 
London, UK) during the visit of MS in 1999 is gratefully acknowledged.
References
1. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott
R, Colombero R, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N,
Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V,
Senaldi G, Guo J, Delaney J, Boyle WJ: Osteoprotegerin ligand is
a cytokine that regulates osteoclast differentiation and
activation. Cell 1998, 93:165-176.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/6
Page 12 of 12
(page number not for citation purposes)
2. Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H,
Shima N, Morinaga T, Toyama Y, Yabe Y, Higashio K, Suda T: Oste-
oclast differentiation factor (ODF) induces osteoclast-like
cell formation in human peripheral blood mononuclear cell
cultures. Biochem Biophys Res Commun 1998, 246:199-204.
3. Shalhoub V, Faust J, Boyle WJ, Dunstan CR, Kelley M, Kaufman S,
Scully S, Van G, Lacey DL: Osteoprotegerin and osteoprote-
gerin ligand effects on osteoclast formation from human
peripheral blood mononuclear cell precursors. J Cell Biochem
1999, 72:251-261.
4. Sarma U, Edwards M, Motoyoshi K, Flanagan AM: Inhibition of bone
resorption by 17beta-estradiol in human bone marrow
cultures. J Cell Physiol 1998, 175:99-108.
5. Mbalaviele G, Jaiswal N, Meng A, Cheng L, Van Den Bos C, Thiede M:
Human mesenchymal stem cells promote human osteoclast
differentiation from CD34+ bone marrow hematopoietic
progenitors. Endocrinology 1999, 140:3736-3743.
6. Nicholson GC, Malakellis M, Collier FM, Cameron PU, Holloway WR,
Gough TJ, Gregorio-King C, Kirkland MA, Myers DE: Induction of
osteoclasts from CD14-positive human peripheral blood
mononuclear cells by receptor activator of nuclear factor
kappaB ligand (RANKL). Clin Sci (Lond) 2000, 99:133-140.
7. Weitzmann MN, Cenci S, Haug J, Brown C, DiPersio J, Pacifici R: B
lymphocytes inhibit human osteoclastogenesis by secretion
of TGFbeta. J Cell Biochem 2000, 78:318-324.
8. Scopes J, Massey HM, Flanagan AM: TGFb enhances human oste-
oclast formation and bone resorption at the expense of
macrophages. J Bone Miner Res 2000, 15:s265.
9. James IE, Lark MW, Zembryki D, Lee-Rykaczewski EV, Hwang SM,
Tomaszek TA, Belfiore P, Gowen M: Development and charac-
terization of a human in vitro resorption assay: demonstra-
tion of utility using novel antiresorptive agents. J Bone Miner
Res 1999, 14:1562-1569.
10. Lader CS, Flanagan AM: Prostaglandin E2, interleukin 1alpha,
and tumor necrosis factor-alpha increase human osteoclast
formation and bone resorption in vitro.  Endocrinology 1998,
139:3157-3164.
11. Massey HM, Scopes J, Horton MA, Flanagan AM: Transforming
growth factor-beta1 (TGF-beta) stimulates the osteoclast-
forming potential of peripheral blood hematopoietic precur-
sors in a lymphocyte-rich microenvironment.  Bone 2001,
28:577-582.
12. David JP, Neff L, Chen Y, Rincon M, Horne WC, Baron R: A new
method to isolate large numbers of rabbit osteoclasts and
osteoclast-like cells: application to the characterization of
serum response element binding proteins during osteoclast
differentiation. J Bone Miner Res 1998, 13:1730-1738.
13. Taranta A, Brama M, Teti A, De Luca V, Scandurra R, Spera G, Agnus-
dei D, Termine JD, Migliaccio S: The selective estrogen receptor
modulator raloxifene regulates osteoclast and osteoblast
activity in vitro. Bone 2002, 30:368-376.
14. Parikka V, Lehenkari P, Sassi ML, Halleen J, Risteli J, Harkonen P,
Vaananen HK: Estrogen reduces the depth of resorption pits
by disturbing the organic bone matrix degradation activity of
mature osteoclasts. Endocrinology 2001, 142:5371-5378.
15. Kung Sutherland MS, Lipps SG, Patnaik N, Gayo-Fung LM, Kham-
mungkune S, Xie W, Brady HA, Barbosa MS, Anderson DW, Stein B:
SP50 a novel SERM, blocks osteoclastogenesis in a human
bone cell model: role of IL-6 and GM-CSF.  Cytokine 0263,
23:1-14.
16. Green JR: Preclinical pharmacology of zoledronic acid. Semin
Oncol 2002, 29:3-11.
17. Reszka AA, Rodan GA: Bisphosphonate mechanism of action.
Curr Rheumatol Rep 2003, 5:65-74.
18. Shevde NK, Bendixen AC, Dienger KM, Pike JW: Estrogens sup-
press RANK ligand-induced osteoclast differentiation via a
stromal cell independent mechanism involving c-Jun
repression. Proc Natl Acad Sci U S A 2000, 97:7829-7834.
19. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, Oste-
oporosis Methodology Group and The Osteoporosis Research Advi-
sory Group: Meta-analyses of therapies for postmenopausal
osteoporosis. IX: Summary of meta-analyses of therapies for
postmenopausal osteoporosis. Endocr Rev 2002, 23:570-578.